18 June 2013
Keywords: Javelin Pharmaceuticals, Ereska, orthopedic surgery
Article | 11 August 2009
USA-based Javelin Pharmaceuticals saw its share price plummet almost 30% to $1.45, after the company revealed that one of its investigational drugs ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 August 2009
© 2013 thepharmaletter.com